The FDA granted orphan-drug designation to ImmunoGen's lorvotuzumab mertasine as a treatment for small-cell lung cancer. The treatment previously obtained orphan-drug status for Merkel cell carcinoma in the U.S. and Europe.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||